An observational study in Inflammatory Bowel Disease and Fatty Liver, sponsored by Tel-Aviv Sourasky Medical Center. Terminated at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-16.
Sponsored by Tel-Aviv Sourasky Medical Center · Observational
Fatty liver is known to be one of the most frequent liver pathologies in IBD patients (35-40%). Despite this fact, there are only few publications that evaluated the prevalence of fatty liver in IBD patients. Moreover, the pathogenesis of this phenomenon in IBD has not been widely investigated.
The paradox of lean patients and fatty liver can be explained by high use of steroids, by rapid weight loss, and by the abundance of TNFα cytokine in IBD patients that causes insulin resistance.
The aim of the study:
To evaluate the frequency of fatty liver in a cohort of IBD patients and to learn its risk factors.
Methods:
One hundred consecutive IBD patients treated at the Tel Aviv Sourasky Medical Center will be recruited.
Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.
Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography.
963 studies on the registry are indexed under Intestinal Diseases; 174 are open to participants now.
This study's enrollment of 100 is below the median of 140 across 377 observational studies indexed under Intestinal Diseases.
Browse Intestinal Diseases studies →Tel-Aviv Sourasky Medical Center is the lead sponsor of 541 studies on the registry; 49 are open to participants now.
Counted across the registry records on this site, refreshed daily.
One hundred consecutive IBD patients treated at the Tel Aviv Sourasky Medical Center will be recruited.
Exclusion Criteria:
IBD patients above the age of 18 years old, suffering from the disease for at least one year.
Other: clinical evaluation
Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome. Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography.
inflammation and metabolic status
Time frame: first visit
Assessment of Fatty liver
Time frame: first visit
This study is terminated, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tel-Aviv Sourasky Medical Center